Latest Period
Q4 2025
Security Snapshot
Nurix Therapeutics, Inc. - COMMON STOCK (NRIX) Institutional Ownership
CUSIP: 67080M103
13F Institutional Holders and Ownership History from Q3 2020 to Q1 2026
Institutions Reporting
182
Shares (Excl. Options)
113,423,406
Price
$18.97
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Type / Class
- Equity / COMMON STOCK
- Symbol
- NRIX on Nasdaq
- Shares outstanding
- 102,616,132
- Price per share
- $15.51
- All holders as of 31 Dec 2025
- Q4 2025
- Total 13F shares
- 113,423,406
- Total reported value
- $2,151,627,911
- % of total 13F portfolios
- 0%
- Share change
- +26,553,310
- Value change
- +$525,564,750
- Number of holders
- 182
- Price from insider filings
- $15.51
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors
Quick Takeaways
- NRIX - Nurix Therapeutics, Inc. - COMMON STOCK is tracked under CUSIP 67080M103.
- 182 institutions reported positions in Q4 2025.
- 7 significant owners is listed from Schedule 13D/13G reporting.
What Changed
- Holder count moved from 182 to 63 between Q4 2025 and Q1 2026.
- Reported value moved from $2,151,627,911 to $300,183,760.
Why This Matters
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Source Evidence
Source: SEC Form 13F
Open SEC Evidence
Latest holder context comes from 182 institutions filings for Q4 2025.
Investment Quick Answers
What is CUSIP 67080M103?
CUSIP 67080M103 identifies NRIX - Nurix Therapeutics, Inc. - COMMON STOCK in SEC 13F datasets.
Where can I see the latest institutional holders?
Review the Q4 2025 holders report and the ownership history table below.
Next ownership checks
Use the next link that matches the question you still need to answer about this security.
- Latest 13F filings when you want to inspect fresh institutional portfolio moves.
- Latest Schedule 13D/13G reports when you need large-owner changes outside the 13F cycle.
- All institutional ownership pages to compare this security with other holder-history pages.
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 67080M103:
Significant Owners of Nurix Therapeutics, Inc. - COMMON STOCK (NRIX) based on Schedule 13D/G filings
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| Redmile Group, LLC | 9.9% | $165,792,867 | 10,696,314 | Redmile Group, LLC | 20 Apr 2026 | |||
| BAKER BROS. ADVISORS LP | 7.2% | $138,364,566 | 7,527,996 | Baker Bros. Advisors LP | 31 Dec 2025 | |||
| BlackRock, Inc. | 8.2% | $72,644,381 | 6,284,116 | BlackRock, Inc. | 31 Mar 2025 | |||
| FMR LLC | 5.4% | +32% | $85,945,115 | +$21,424,444 | 5,541,271 | +33% | FMR LLC | 31 Mar 2026 |
| Deep Track Capital, LP | 7.2% | +35% | $63,580,000 | +$15,895,000 | 5,500,000 | +33% | Deep Track Capital, LP | 31 Mar 2025 |
| Commodore Capital LP | 4.9% | -4% | $34,927,708 | -$646,292 | 3,780,055 | -1.8% | Commodore Capital LP | 30 Sep 2025 |
| WELLINGTON MANAGEMENT GROUP LLP | 4.2% | $36,861,858 | 3,188,742 | Wellington Management Group LLP | 31 Mar 2025 |
As of 31 Dec 2025, 182 institutional investors reported holding 113,423,406 shares of Nurix Therapeutics, Inc. - COMMON STOCK (NRIX). This represents 111% of the company’s total 102,616,132 outstanding shares.
Top 25 Institutional Shareholders
The largest institutional shareholders of Nurix Therapeutics, Inc. - COMMON STOCK (NRIX) together control 89% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| BlackRock, Inc. | 8.6% | 8,875,194 | +31% | 0% | $168,362,430 |
| Redmile Group, LLC | 7.9% | 8,093,908 | +120% | 11% | $153,541,435 |
| Deep Track Capital, LP | 6.9% | 7,036,455 | +16% | 3% | $133,481,551 |
| VANGUARD GROUP INC | 5.8% | 5,949,512 | +33% | 0% | $112,862,243 |
| GENERAL ATLANTIC, L.P. | 4.8% | 4,897,159 | 3.2% | $92,899,106 | |
| MORGAN STANLEY | 4.8% | 4,881,068 | +116% | 0.01% | $92,593,872 |
| Vestal Point Capital, LP | 4.6% | 4,690,000 | +35% | 3.3% | $88,969,300 |
| BAKER BROS. ADVISORS LP | 4.5% | 4,658,556 | +20% | 0.52% | $88,372,807 |
| FMR LLC | 4.1% | 4,234,158 | -52% | 0% | $80,321,977 |
| STATE STREET CORP | 3.5% | 3,559,501 | +24% | 0% | $67,523,734 |
| PERCEPTIVE ADVISORS LLC | 3.5% | 3,555,877 | +151% | 1.2% | $67,454,987 |
| Pictet Asset Management Holding SA | 3.4% | 3,467,600 | +75% | 0.06% | $65,780,372 |
| PRICE T ROWE ASSOCIATES INC /MD/ | 3.2% | 3,248,361 | +196% | 0.01% | $61,622,000 |
| Point72 Asset Management, L.P. | 3.1% | 3,211,680 | +12% | 0.1% | $60,925,570 |
| DEUTSCHE BANK AG\ | 2.4% | 2,486,792 | +73% | 0.02% | $47,174,444 |
| Rubric Capital Management LP | 2.4% | 2,473,885 | 0.56% | $46,929,598 | |
| GEODE CAPITAL MANAGEMENT, LLC | 2.3% | 2,384,998 | +27% | 0% | $45,250,415 |
| Commodore Capital LP | 2.2% | 2,275,000 | -40% | 2.9% | $43,156,750 |
| BRAIDWELL LP | 2.1% | 2,183,864 | 1.3% | $41,427,900 | |
| Kynam Capital Management, LP | 1.9% | 1,970,357 | -9.1% | 2.4% | $37,377,672 |
| Trails Edge Capital Partners, LP | 1.7% | 1,743,220 | 0% | 8.2% | $33,068,884 |
| ARK Investment Management LLC | 1.6% | 1,602,539 | +6.1% | 0.2% | $30,400,171 |
| EVENTIDE ASSET MANAGEMENT, LLC | 1.3% | 1,297,893 | 0.38% | $24,621,030 | |
| Sumitomo Mitsui Trust Group, Inc. | 1.3% | 1,290,554 | -17% | 0.01% | $24,481,809 |
| Amova Asset Management Americas, Inc. | 1.3% | 1,290,554 | -17% | 0.28% | $24,481,809 |
Institutional Holders of Nurix Therapeutics, Inc. - COMMON STOCK (NRIX) across Reporting Periods
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 19,368,761 | $300,183,760 | +$2,473,937 | $15.50 | 63 |
| 2025 Q4 | 113,423,406 | $2,151,627,911 | +$525,564,750 | $18.97 | 182 |
| 2025 Q3 | 84,776,704 | $783,330,709 | -$36,480,592 | $9.24 | 171 |
| 2025 Q2 | 88,319,847 | $1,005,944,844 | +$40,932,248 | $11.39 | 161 |
| 2025 Q1 | 84,604,598 | $1,005,122,777 | +$28,667,924 | $11.88 | 168 |
| 2024 Q4 | 81,104,522 | $1,528,053,172 | +$225,677,197 | $18.84 | 173 |
| 2024 Q3 | 67,877,304 | $1,525,459,447 | +$59,100,303 | $22.47 | 170 |
| 2024 Q2 | 64,996,165 | $1,356,466,249 | +$340,051,233 | $20.87 | 172 |
| 2024 Q1 | 49,045,600 | $720,957,554 | +$50,639,301 | $14.70 | 138 |
| 2023 Q4 | 46,078,653 | $475,525,962 | +$17,732,104 | $10.32 | 127 |
| 2023 Q3 | 44,845,094 | $352,482,854 | +$8,466,362 | $7.86 | 129 |
| 2023 Q2 | 43,637,466 | $435,668,849 | +$11,852,256 | $9.99 | 124 |
| 2023 Q1 | 42,478,076 | $376,567,538 | -$3,101,624 | $8.88 | 121 |
| 2022 Q4 | 42,696,157 | $468,798,220 | +$2,144,188 | $10.98 | 119 |
| 2022 Q3 | 43,069,388 | $561,182,776 | -$38,324,545 | $13.03 | 114 |
| 2022 Q2 | 44,940,935 | $567,552,048 | +$55,435,115 | $12.67 | 100 |
| 2022 Q1 | 40,367,078 | $565,503,716 | -$19,332,926 | $14.01 | 111 |
| 2021 Q4 | 40,421,865 | $1,170,057,078 | +$25,875,537 | $28.95 | 121 |
| 2021 Q3 | 39,378,816 | $1,180,362,633 | -$11,970,711 | $29.96 | 110 |
| 2021 Q2 | 39,520,770 | $1,048,795,893 | -$66,662,023 | $26.53 | 103 |
| 2021 Q1 | 41,346,108 | $1,285,407,277 | +$254,357,641 | $31.09 | 99 |
| 2020 Q4 | 33,136,833 | $1,089,462,176 | +$26,868,033 | $32.88 | 67 |
| 2020 Q3 | 31,854,383 | $1,111,189,598 | +$1,111,189,598 | $34.91 | 64 |